Longeveron Q2 FY26 earnings call LGVN

Longeveron's primary focus is its Hypoplastic Left Heart Syndrome (HLHS) program, with top-line results from the ELPAS-2 Phase 2b clinical trial evaluating laramester cell anticipated in mid-September. The trial is assessing objective measures including all-cause mortality, cardiac transplant-free survival, and major adverse cardiac events, which the FDA considers informative for efficacy. Management believes that if successful, these data could lead to BLA filing and potential approval, leveraging existing FDA flexibility for rare pediatric diseases.

The company's laramester cell therapy was selected as a finalist for the XPRIZE HealthSpan competition, receiving a $1 million award. This recognition validates the therapy's potential to increase six-minute walk distance in patients with age-related frailty, with clinical trials expected to continue through 2029. Longeveron is the only public company among the finalists, highlighting its position in cutting-edge longevity research.

Longeveron is planning for a potential initiation in 2027 of a Phase 2 clinical trial for pediatric dilated cardiomyopathy (PDCM), a rare and serious cardiovascular disease. The IND application for laramester cell in PDCM became effective in July 2025, allowing direct advancement into a single Phase 2 registration trial, reflecting the high unmet medical need and regulatory flexibility for this indication.

Management emphasized exploring potential development and commercialization partnerships for laramester cell across its programs. They believe leveraging established pharmaceutical partners' commercial infrastructure, capital resources, and global reach represents the most efficient pathway to unlock the full value of their assets, particularly following the anticipated positive HLHS data.

For Q2 2026, Longeveron reported revenues of $0.3 million, a 10% decrease year-over-year due to the absence of contract manufacturing revenue. General and administrative expenses increased by 23% to $3.2 million, driven by higher legal and personnel costs, while R&D expenses rose 7% to $3.2 million due to increased clinical trial activities. The net loss for the quarter was $6.1 million, up 22% from the prior year. The company's cash and cash equivalents of $10.1 million are projected to fund operations into Q4 2026.

Laramester cell is supported by strong foundational science, including multiple potential mechanisms of action (anti-inflammatory, provascular, pro-regenerative effects) and a portfolio of 52 issued patents. The therapy has received five FDA expedited designations, including Regenerative Medicine Advanced Therapy (RMAT), Fast-Track, Orphan Drug, and Rare Pediatric Disease, underscoring its potential and the urgent need for new treatments in its target indications.

Longeveron has had substantive discussions with the FDA regarding its Statistical Analysis Plan (SAP) for the ELPAS-2 trial, incorporating agency feedback on endpoint strategy. While awaiting final FDA comments on the SAP, the company intends to proceed with database lock and analysis based on the finalized plan. Management expressed confidence that even if the former primary endpoint (RVEF) is not met, improvements in clinically significant exploratory endpoints like transplant-free survival and hospitalization could support a BLA submission, given the unmet need and FDA's regulatory flexibility.

The company is collecting long-term patient outcome data for the HLHS trial, with some patients having up to five years of data. They are also planning a long-term extension trial to follow patients up to 10 years of age, which has been discussed with the FDA. This comprehensive data collection aims to provide sufficient evidence for long-term survival and transplant-free survival, which are considered critical for regulatory approval, potentially supporting accelerated or traditional BLA pathways.